

bodied applicants and recipients to do job search for up to 16 weeks unless otherwise exempted; terminate the case when there is loss of contact with the client for 1 month after nonpayment for failure to meet the performance requirements; exclude the earned income and resources of a dependent child who is a full-time high school student; allow payment of the supplied shelter grant for households with a SSI recipient, unmarried minor parents, or recipients disqualified for other reasons (fraud, education time limits, illegal aliens); exclude one licensed vehicle with a fair market value of less than \$12,000; increase the resource limit to \$2,500 for those in compliance with, or exempted from, the performance requirements; and exclude veteran's service connected disability compensation if the annual income is less than the poverty level.

Date Received: 5/13/96.

Type: Combined AFDC/Medicaid.

Current Status: Pending.

Contact Person: Marianne Lee, (307) 777-6849.

III. Listing of Approved Proposals Since July 1, 1995

Project Title: Tennessee—Families First.

Contact Person: Glenda Shearon, (615) 313-5652.

Project Title: Utah—Single-Parent Employment Demonstration (Amendments).

Contact Person: Bill Biggs, (801) 538-4337.

IV. Requests for Copies of a Proposal

Requests for copies of an AFDC or combined AFDC/Medicaid proposal should be directed to the Administration for Children and Families (ACF) at the address listed above. Questions concerning the content of a proposal should be directed to the State contact listed for the proposal.

(Catalog of Federal Domestic Assistance Program, No. 93562; Assistance Payments—Research)

Dated: August 12, 1996.

Howard Rolston,

Director, Office of Planning, Research and Evaluation.

[FR Doc. 96-20938 Filed 8-15-96; 8:45am]

BILLING CODE 4184-01-P

Food and Drug Administration

[Docket No. 93F-0269]

Lonza, Inc.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 3B4387), proposing that the food additive regulations be amended to provide for the safe use of didecyldimethylammonium chloride as a preservative on wooden articles intended to contact food.

FOR FURTHER INFORMATION CONTACT:

Andrew J. Zajac, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3095.

SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of August 12, 1993 (58 FR 42977), FDA announced that a food additive petition (FAP 3B4387) had been filed on behalf of Lonza, Inc., c/o Delta Analytical Corp., 7910 Woodmont Ave., suite 1000, Bethesda, MD 20814 (currently c/o Lewis & Harrison, 122 C St. NW., suite 740, Washington, DC 20001).

The petition proposed to amend the food additive regulations in § 178.3800 *Preservatives for wood* (21 CFR 178.3800) to provide for the safe use of didecyldimethylammonium chloride as a preservative on wooden articles intended to contact food. Lonza, Inc., has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: July 19, 1996.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 96-20964 Filed 8-15-96; 8:45 am]

BILLING CODE 4160-01-F

[Docket Nos. 80N-0012 and 84N-0067; DESI 10826]

Drug Efficacy Study Implementation; Certain Topical Anti-Infective Drug Products; Withdrawal of Approval of New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of pertinent parts of the new drug applications (NDA's) for cream and ointment products containing neomycin sulfate and gramicidin in addition to nystatin and triamcinolone acetonide. There is a lack of substantial evidence that the products as originally formulated are effective in the treatment of various dermatoses and as anti-infective agents for which they are

labeled. Both products have been reformulated to eliminate neomycin sulfate and gramicidin, and FDA has approved the reformulated products as safe and effective.

EFFECTIVE DATE: September 16, 1996.

ADDRESSES: Requests for guidance on the applicability of this notice to a specific product should be identified with the Drug Efficacy Study Implementation (DESI) number 10826 and directed to the Division of Prescription Drug Compliance and Surveillance (HFD-330), Center for Drug Evaluation and Research, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.

FOR FURTHER INFORMATION CONTACT:

Christine F. Rogers, Center for Drug Evaluation and Research (HFD-366), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-2041.

SUPPLEMENTARY INFORMATION: In a notice of opportunity for a hearing published in the Federal Register of September 25, 1981 (46 FR 47408), the Director of the Bureau of Drugs (now the Center for Drug Evaluation and Research) proposed to withdraw approval of NDA's for certain topical anti-infective drug products. The proposal was based on the lack of substantial evidence of effectiveness as required by section 505(e) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(e)) and 21 CFR 314.126 (previously 21 CFR 314.111(a)(5)). In response to that notice, requests for a hearing were filed for the following NDA's:

1. NDA's 60-572 and 60-576; Mycolog Ointment and Cream, respectively, both containing nystatin (100,000 units per gram (g)), triamcinolone acetonide (1.0 milligram (mg)/g), neomycin sulfate (2.5 mg/g), and gramicidin (0.25 mg/g); now held by Apothecon, a division of Bristol-Myers Squibb, P.O. Box 4500, Princeton, NJ 08543-4500.

2. NDA's 61-954 and 62-045; Myco Triacet Cream and Ointment, respectively, containing nystatin, neomycin sulfate, gramicidin, and triamcinolone acetonide; held by Lemmon Co., 650 Cathill Rd., Sellersville, PA 18960.

3. NDA's 62-135 and 62-136; Nystatin-Neomycin Sulfate-Gramicidin-Triamcinolone Acetonide Ointment and Cream, respectively; held by E. Fougera and Co. (formerly Byk Pharmaceutical Group), a division of Altana, Inc., 60 Baylis Rd., Melville, NY 11747.

4. NDA's 62-186 and 62-280; Nystatin-Neomycin Sulfate-Gramicidin-Triamcinolone Acetonide Cream and Ointment, respectively; held by Clay-